Neurocrine Biosciences NBIX
-
7 Undervalued Healthcare Stocks Being Bought Up By Hedge Funds
By Kapitall : Do you consider yourself a value investor, always looking for underestimated and potentially undervalued stocks? For ideas on how to start your own value search, we ran a screen. We began by screening for stocks that appear to be undervalued relative to earnings growth, with PEG below
-
Neurocrine Biosciences' CEO Presents at Deutsche Bank 37th Annual Health Care Conference (Transcript)
Neurocrine Biosciences , Inc. ( NBIX ) Deutsche Bank 37th Annual Health Care Conference Call May ..... Deutsche Bank Biotechnology Analyst, and up next we have Neurocrine Biosciences and representing the company is Kevin Gorman, Chief Executive …
-
Neurocrine Biosciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Neurocrine Biosciences Inc. ( NBIX ) Q1 2012 Earnings Call May ..... day everyone and welcome to Neurocrine Biosciences reports first quarter 2012 ..... Gorman, President and CEO of Neurocrine Biosciences . Please go ahead sir. Kevin …
-
Small-Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
By Ganaxi Small Cap Movers : The biotech group as represented by the NYSE ARCA Biotech Index ($BTK) has been strong this year, now up over 27% YTD, and still trending higher. With both the market and the biotech sector in strong bull mode, now maybe an opportune time to go 'shop' for biotech ...
-
Neurocrine's News Not As Bad As The Market Thinks
… in their gains. That's about the only explanation that makes much sense to me when seeing how shares of Neurocrine Biosciences ( NBIX ) are responding to news regarding results from a Phase 2 study and its upcoming pivotal Phase 3 study for …
-
Neurocrine Biosciences' CEO Reviews Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia (Transcript)
Neurocrine Biosciences Inc. ( NBIX ) Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia Call March 27, 2012 08:00 am ET Executives …
-
Neurocrine Biosciences ( NBIX ) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary endpoint, when a site featuring ...
Neurocrine Biosciences ( NBIX ) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary …
-
Neurocrine Could Be A Major Biotech Comeback Story
… there are companies that rebound from major disappointment and go on to considerable success. Not only does Neurocrine Biosciences ( NBIX ) look like one such story, but the potential of these shares is such that even a conservative analysis …
-
Neurocrine Biosciences' CEO Presents at 30th Annual JPMorgan Global Healthcare Conference - Conference Call Transcript
Neurocrine Biosciences , Inc. ( NBIX ) 30th Annual JPMorgan Global Healthcare Conference Call January 12, 2012 5:00 pm ET Executives Kevin Gorman - President and …
-
Neurocrine Biosciences' CEO Citi 2012 Global Health Care Conference (Transcript)
Neurocrine Biosciences ( NBIX ) Citi 2012 Global Health Care Conference Call February 29, 2012 11:00 AM ET Executives Kevin Gorman – President and CEO Presentation …